Wegovy vs Zepbound

Receptor mechanism: GLP-1 vs dual GIP/GLP-1

Wegovy activates one metabolic receptor. Zepbound activates two. This biological distinction explains why the two medications behave differently in clinical trials and why their milligram doses cannot be compared directly.

Wegovy (semaglutide): A selective glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the native GLP-1 incretin hormone secreted by intestinal L-cells after meals. Wegovy acts on hypothalamic appetite centers to reduce hunger, dampens dopamine-driven food cravings ("food noise"), and slows gastric emptying so meals keep you full longer.

Zepbound (tirzepatide): A dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. While GLP-1 suppresses appetite and slows digestion, GIP acts directly on subcutaneous adipose tissue to improve insulin sensitivity, accelerate lipid turnover, and modulate energy expenditure. Furthermore, central GIP signaling appears to buffer the severe nausea and malaise frequently triggered by high-dose GLP-1 stimulation alone.

SURMOUNT-5 head-to-head trial results

Until recently, comparisons between Wegovy and Zepbound relied on cross-trial comparisons between the STEP and SURMOUNT programs. In 2024–2025, the SURMOUNT-5 randomized clinical trial delivered the first direct, head-to-head comparison.

SURMOUNT-5 randomized 751 adults with obesity (BMI ≥30, or ≥27 with weight-related comorbidities) and without diabetes to maximum tolerated doses of tirzepatide (up to 15 mg) or semaglutide (up to 2.4 mg) for 72 weeks.

Zepbound demonstrated statistical superiority across both weight reduction and cardiometabolic secondary endpoints, including fasting triglycerides, blood pressure, and HbA1c. Crucially, gastrointestinal tolerability favored Zepbound: fewer patients stopped tirzepatide due to nausea, vomiting, or diarrhea than stopped semaglutide (2.7% vs 5.6%).

Cardiovascular outcomes and secondary indications

While Zepbound leads on raw weight loss, Wegovy holds the most definitive cardiovascular evidence in the obesity field.

In the landmark SELECT trial (17,604 participants followed for a median of 39.8 months), Wegovy 2.4 mg reduced the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 20% relative to placebo (6.5% vs 8.0%). This led the FDA in March 2024 to approve Wegovy specifically to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity.

Zepbound is not without secondary indications. In late 2024, the FDA approved Zepbound for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, based on the SURMOUNT-OSA trials showing an average reduction of ~25 to 30 apnea/hypopnea events per hour. Tirzepatide's dedicated cardiovascular outcomes trial (SURPASS-CVOT) is currently completing follow-up.

3-way comparison matrix: Wegovy vs Zepbound vs Compounded

Patients evaluating Wegovy and Zepbound often face insurance denials and consider compounded alternatives. Here is how brand Wegovy, brand Zepbound, and compounded peptides compare across clinical, regulatory, and financial dimensions:

Titration schedules and maintenance tiers

Both medications require gradual monthly dose escalation to minimize gastrointestinal distress. However, their dose ladders structure maintenance differently.

The maintenance difference: Zepbound gives prescribers significant flexibility. Patients who achieve excellent appetite suppression and fat loss on 5 mg or 10 mg can remain on those doses permanently. Wegovy's FDA prescribing information designates 2.4 mg as the sole chronic maintenance dose (with 1.7 mg allowed only for patients who cannot tolerate 2.4 mg). Use our titration schedule tool to map your dates.

How to switch between Wegovy and Zepbound

Patients switch between Wegovy and Zepbound for four primary reasons: hitting a stubborn weight loss plateau on semaglutide, intolerable nausea or reflux, insurance formulary exclusions, or pharmacy supply shortages.

Check the GLP-1 dose conversion tool to see how dose steps map between products.

Cost, insurance coverage, and telehealth access

The financial reality: List prices for both medications exceed $1,000 per month out of pocket. Insurance coverage is the primary determinant of which drug a patient actually takes.

• Commercial Insurance & Formularies: Many employer health plans exclude anti-obesity medications entirely. When covered, plans typically favor one drug over the other based on manufacturer rebate contracts, requiring prior authorizations (PA) confirming a BMI ≥30 or ≥27 with hypertension or dyslipidemia.
• LillyDirect Self-Pay Vials: Eli Lilly introduced single-dose self-pay vials for Zepbound at 2.5 mg ($399/month) and 5.0 mg ($549/month) through its direct-to-consumer pharmacy, substantially undercutting the retail cash price of brand pens.
• Compounded Multi-Dose Vials: When insurance coverage is denied, patients frequently turn to state-licensed 503A or FDA-registered 503B compounding pharmacies. Compounded semaglutide averages $178–$299/month, while compounded tirzepatide averages $280–$399/month. See our compounded GLP-1 cost guide for 2026 telehealth pricing models.

Common questions

Is Zepbound stronger than Wegovy?

Yes, in terms of clinical weight loss. In the head-to-head SURMOUNT-5 trial, Zepbound (tirzepatide) produced 20.2% mean body weight loss versus 13.7% for Wegovy (semaglutide) over 72 weeks. Zepbound co-activates both GIP and GLP-1 receptors, creating greater appetite suppression and metabolic signaling.

Can I switch from Wegovy to Zepbound if I hit a weight loss plateau?

Yes, switching is common under medical supervision. Many patients who stop losing weight on Wegovy 2.4 mg experience renewed weight reduction after transitioning to Zepbound. However, you must wait 7 days after your last Wegovy dose and re-titrate from a lower starting dose (usually 2.5 mg or 5 mg) rather than starting at 15 mg.

Why did Zepbound beat Wegovy in SURMOUNT-5?

Zepbound is a dual agonist targeting both GIP and GLP-1 receptors. GIP receptor activation enhances insulin sensitivity in subcutaneous fat depots, increases lipid clearance, and works synergistically with GLP-1 in the brain to reduce appetite more effectively than GLP-1 receptor agonism alone.

Does Wegovy have any advantages over Zepbound?

Yes. Wegovy has proven cardiovascular protection from the 17,604-patient SELECT trial, showing a 20% relative reduction in heart attacks, strokes, and cardiovascular deaths, and holds an official FDA indication for CVD risk reduction. Zepbound's dedicated cardiovascular outcomes trial is still completing follow-up.

Why is Zepbound cheaper than Wegovy?

Brand Zepbound lists slightly lower ($1,059 vs $1,349/month), and Eli Lilly offers self-pay 2.5 mg ($399) and 5.0 mg ($549) vials through LillyDirect. However, actual out-of-pocket cost is dictated almost entirely by your specific insurance formulary.

Which drug causes worse nausea and stomach side effects?

In the SURMOUNT-5 head-to-head trial, tolerability slightly favored Zepbound: only 2.7% of participants stopped tirzepatide due to gastrointestinal issues, compared to 5.6% on semaglutide. Researchers hypothesize that GIP receptor co-activation helps buffer against nausea.

Can I stay on a low dose of Zepbound for maintenance?

Yes. Zepbound is FDA-approved for chronic maintenance at three distinct doses: 5 mg, 10 mg, and 15 mg. Wegovy is officially licensed for 2.4 mg maintenance, with 1.7 mg reserved only for those who cannot tolerate 2.4 mg.

What should I do if insurance denies both Wegovy and Zepbound?

If commercial coverage is denied, options include appealing with a detailed letter of medical necessity, using manufacturer copay discount cards (if commercially insured without government coverage), purchasing LillyDirect cash vials, or utilizing legitimate 503A/503B compounded pharmacies ($178–$399/month).

Keep reading